The metabolic role of prolactin: systematic review, meta-analysis and preclinical considerations

References

• Stansfield E, Fischer B, Grunstra NDS, et al. The evolution of pelvic canal shape and rotational birth in humans. BMC Biol. 2021 Oct 11 19(1):224.
   PubMed Web of Science ®Google Scholar
• Wittman AB, Wall LL. The evolutionary origins of obstructed labor: bipedalism, encephalization, and the human obstetric dilemma. Obstet Gynecol Surv. 2007 Nov;62(11):739–748.
   PubMed Web of Science ®Google Scholar
• Li Y, Wallis M, Zhang YP. Episodic evolution of prolactin receptor gene in mammals: coevolution with its ligand. J Mol Endocrinol. 2005 Dec;35(3):411–419.
   PubMed Web of Science ®Google Scholar
• Ni Y, Chen Q, Cai J, et al. Three lactation-related hormones: regulation of hypothalamus-pituitary axis and function on lactation. Mol Cell Endocrinol. 2021 Jan 15;520:111084. .
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Pijl H, Keenan DM, et al. Prolactin secretion in healthy adults is determined by gender, age and body mass index. PLoS One. 2012;7(2):e31305.
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, McLachlan SM, Hwe J, et al. Insulin-like growth factor 1 and prolactin levels in chimpanzees (Pan troglodytes) across the lifespan. J Endocr Soc. 2021 Aug 1 5(8):bvab063.
   PubMed Web of Science ®Google Scholar
• Moriwaki M, Welt CK. PRL mutation causing alactogenesis: insights into prolactin structure and function Relationships. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3021–e3026.
   PubMed Web of Science ®Google Scholar
• Bachelot A, Binart N. Reproductive role of prolactin. Reproduction. 2007 Feb;133(2):361–369.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Maggi M. The role of prolactin in andrology: what is new? Rev Endocr Metab Disord. 2015 Sep;16(3):233–248.
   PubMed Web of Science ®Google Scholar
• Lotti F, Corona G, Maseroli E, et al. Clinical implications of measuring prolactin levels in males of infertile couples. Andrology. 2013 Sep;1(5):764–771.
   PubMed Web of Science ®Google Scholar
• Garcia A, Herbon L, Barkan A, et al. Hyperprolactinemia inhibits gonadotropin-releasing hormone (GnRH) stimulation of the number of pituitary GnRH receptors. Endocrinology. 1985 Sep;117(3):954–959.
   PubMed Web of Science ®Google Scholar
• Forbes AP, Henneman PH, Griswold GC, et al. Syndrome characterized by galactorrhea, amenorrhea and low urinary FSH: comparison with acromegaly and normal lactation. J Clin Endocrinol Metab. 1954 Mar;14(3):265–271.
   PubMed Web of Science ®Google Scholar
• Corona G, Isidori AM, Aversa A, et al. Endocrinologic control of men’s sexual desire and arousal/erection. J Sex Med. 2016 Mar;13(3):317–337.
   PubMed Web of Science ®Google Scholar
• Corona G, Mannucci E, Fisher AD, et al. Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. J Sex Med. 2007 Sep;4(5):1485–1493.
   PubMed Web of Science ®Google Scholar
• Corona G, Mannucci E, Jannini EA, et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med. 2009 May;6(5):1457–1466.
   PubMed Web of Science ®Google Scholar
• Lopez-Vicchi F, De Winne C, Brie B, et al. Metabolic functions of prolactin: physiological and pathological aspects. J Neuroendocrinol. 2020 Nov;32(11):e12888.
   PubMed Web of Science ®Google Scholar
• Macotela Y, Triebel J, Clapp C. Time for a New Perspective on Prolactin in Metabolism. Trends Endocrinol Metab. 2020 Apr;31(4):276–286.
   PubMed Web of Science ®Google Scholar
• Maneschi E, Cellai I, Aversa A, et al. Tadalafil reduces visceral adipose tissue accumulation by promoting preadipocytes differentiation towards a metabolically healthy phenotype: studies in rabbits. Mol Cell Endocrinol. 2016 Mar 15;424:50–70.
   PubMed Web of Science ®Google Scholar
• Maneschi E, Morelli A, Filippi S, et al. Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. J Endocrinol. 2012 Dec;215(3):347–362.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Filippi S, Comeglio P, et al. Metformin in vitro and in vivo increases adenosine signaling in rabbit corpora cavernosa. J Sex Med. 2014 Jul;11(7):1694–1708.
   PubMed Web of Science ®Google Scholar
• Corona G, Filippi S, Bianchi N, et al. Cardiovascular risks of androgen deprivation therapy for prostate cancer. World J Mens Health. 2021 Jul;39(3):429–443.
   PubMedGoogle Scholar
• Corona G, Rastrelli G, Vignozzi L, et al. The Role of testosterone treatment in patients with metabolic disorders. Expert Rev Clin Pharmacol. 2021 Sep;14(9):1091–1103.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Boddi V, et al. Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Int J Androl. 2011 Jun;34(3):217–224.
   PubMedGoogle Scholar
• Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf). 1998 May;48(5):547–553.
   PubMed Web of Science ®Google Scholar
• Yavuz D, Deyneli O, Akpinar I, et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol. 2003 Sep;149(3):187–193.
   PubMed Web of Science ®Google Scholar
• Tuzcu A, Bahceci M, Dursun M, et al. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest. 2003 Apr;26(4):341–346.
   PubMed Web of Science ®Google Scholar
• Serri O, Li L, Mamputu JC, et al. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006 Apr;64(4):366–370.
   PubMed Web of Science ®Google Scholar
• Naliato EC, Violante AH, Caldas D, et al. Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol (Oxf). 2007 Dec;67(6):845–852.
   PubMed Web of Science ®Google Scholar
• Erem C, Kocak M, Nuhoglu I, et al. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf). 2010 Oct;73(4):502–507.
   PubMed Web of Science ®Google Scholar
• de Assunção Alves Rodrigues Lf, Campos SM, Miranda PA, et al. Prolactinoma: a condition associated with hypoadiponectinemia. Horm Metab Res. 2012 Oct;44(11):832–838.
   PubMed Web of Science ®Google Scholar
• Reuwer AQ, Sondermeijer BM, Battjes S, et al. Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study. Pituitary. 2012 Dec;15(4):472–481.
   PubMed Web of Science ®Google Scholar
• Corona G, Wu FC, Rastrelli G, et al. Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European male aging study (EMAS). J Sex Med. 2014 Jan;11(1):240–253.
   PubMed Web of Science ®Google Scholar
• Jiang XB, Li CL, He DS, et al. Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study. Pituitary. 2014 Jun;17(3):232–239.
   PubMed Web of Science ®Google Scholar
• Breyer Freitas B, Rothen RE, Zeni D, et al. Nutritional and metabolic assessment in overweight patients with and without hyperprolactinemia caused by prolactinoma. Nutr Hosp. 2015 Nov 1 32(5):2030–2037.
   PubMed Web of Science ®Google Scholar
• Delibaşı T, Arslan MS, Çakal E, et al. Hyperprolactinemia has no effect on plasma ghrelin levels in patients with prolactinoma. J Turk Ger Gynecol Assoc. 2015;16(2):86–90.
   PubMedGoogle Scholar
• Medic-Stojanoska M, Icin T, Pletikosic I, et al. Risk factors for accelerated atherosclerosis in young women with hyperprolactinemia. Med Hypotheses. 2015 Apr;84(4):321–326.
   PubMed Web of Science ®Google Scholar
• Pala NA, Laway BA, Misgar RA, et al. Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: response to treatment with cabergoline. Indian J Endocrinol Metab. 2016 Mar-Apr;20(2):177–181.
   PubMedGoogle Scholar
• Perić B, Kruljac I, Šundalić S, et al. Obesity and hypercholesterolemia in patients with prolactinomas: could DHEA-S and growth hormone be the missing link? Endocr Res. 2016 Aug;41(3):200–206.
   PubMed Web of Science ®Google Scholar
• Posawetz AS, Trummer C, Pandis M, et al. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study. BMC Endocr Disord. 2021 Apr 26 21(1):81.
   PubMed Web of Science ®Google Scholar
• Doknic M, Pekic S, Zarkovic M, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002 Jul;147(1):77–84.
   PubMed Web of Science ®Google Scholar
• Korner J, Lo J, Freda PU, et al. Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia. Obes Res. 2003 Feb;11(2):311–312.
   PubMedGoogle Scholar
• Steele CA, MacFarlane IA, Blair J, et al. Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes. Eur J Endocrinol. 2010 Oct;163(4):515–522.
   PubMed Web of Science ®Google Scholar
• Berinder K, Nyström T, Höybye C, et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011 Sep;14(3):199–207.
   PubMed Web of Science ®Google Scholar
• Santos-Silva, Dos Santos Silva Cm FRP, Lima FR, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011 Apr;19(4):800–805.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Granieri L, Galdiero M, et al. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology. 2013;98(4):299–310.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Galdiero M, Vitale P, et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology. 2015;101(1):66–81.
   PubMed Web of Science ®Google Scholar
• Ciresi A, Amato MC, Guarnotta V, et al. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf). 2013 Dec;79(6):845–852.
   PubMed Web of Science ®Google Scholar
• Barbosa FR, Silva CM, Lima GA, et al. Prevalence of obstructive sleep apnea in patients with prolactinoma before and after treatment with dopamine agonists. Pituitary. 2014 Oct;17(5):441–449.
   PubMed Web of Science ®Google Scholar
• Schwetz V, Librizzi R, Trummer C, et al. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metab Brain Dis. 2017 Feb;32(1):155–161.
   PubMed Web of Science ®Google Scholar
• Khalil G, Khan FA, Jamal QM, et al. Change in insulin sensitivity and lipid profile after dopamine agonist therapy in patients with prolactinoma. Cureus. 2021 Sep;13(9):e17824.
   PubMed Web of Science ®Google Scholar
• Andereggen L, Frey J, Andres RH, et al. Impact of primary medical or surgical therapy on prolactinoma patients’ BMI and metabolic profile over the long-term. J Clin Transl Endocrinol. 2021 Mar;24:100258.
   PubMedGoogle Scholar
• Pirchio R, Auriemma RS, Solari D, et al. Effects of pituitary surgery and high-dose cabergoline therapy on metabolic profile in patients with prolactinoma resistant to conventional cabergoline treatment. Front Endocrinol (Lausanne). 2021;12:769744.
   PubMed Web of Science ®Google Scholar
• Dewey KG. Energy and protein requirements during lactation. Annu Rev Nutr. 1997;17(1):19–36.
   PubMedGoogle Scholar
• Freemark M, Fleenor D, Driscoll P, et al. Body weight and fat deposition in prolactin receptor-deficient mice. Endocrinology. 2001 Feb;142(2):532–537.
   PubMed Web of Science ®Google Scholar
• Fleenor D, Arumugam R, Freemark M. Growth hormone and prolactin receptors in adipogenesis: STAT-5 activation, suppressors of cytokine signaling, and regulation of insulin-like growth factor I. Horm Res. 2006;66(3):101–110.
   PubMedGoogle Scholar
• Cabrera-Reyes EA, Limón-Morales O, Rivero-Segura NA, et al. Prolactin function and putative expression in the brain. Endocrine. 2017 Aug;57(2):199–213.
   PubMed Web of Science ®Google Scholar
• Leslie M, Silva P, Paloyelis Y, et al. A systematic review and quantitative meta-analysis of oxytocin’s effects on feeding. J Neuroendocrinol. 2018 Feb 26 30(8):e12584.
   Web of Science ®Google Scholar
• Loth MK, Donaldson ZRO. Dopamine, and opioid interactions underlying pair bonding: highlighting a potential role for microglia. Endocrinology. 2021 Feb 1;162(2).
   PubMed Web of Science ®Google Scholar
• Holder JL Jr., Butte NF, Zinn AR. Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. Hum Mol Genet. 2000 Jan 1; 9(1):101–108.
   PubMed Web of Science ®Google Scholar
• Sarchielli E, Comeglio P, Filippi S, et al. Neuroprotective effects of testosterone in the hypothalamus of an animal model of metabolic syndrome. Int J Mol Sci. 2021 Feb 4 22(4):1589.
   PubMed Web of Science ®Google Scholar
• Morelli A, Filippi S, Comeglio P, et al. Physical activity counteracts metabolic syndrome-induced hypogonadotropic hypogonadism and erectile dysfunction in the rabbit. Am J Physiol Endocrinol Metab. 2019 Mar 1 316(3):E519–e535.
   PubMed Web of Science ®Google Scholar
• Morelli A, Sarchielli E, Comeglio P, et al. Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol. 2014 Jan 25 382(1):107–119.
   PubMed Web of Science ®Google Scholar
• Shrivastava V, Lee M, Lee D, et al. Beta cell adaptation to pregnancy requires prolactin action on both beta and non-beta cells. Sci Rep. 2021 May 14 11(1):10372.
   PubMed Web of Science ®Google Scholar
• Reuwer AQ, Twickler MT, Hutten BA, et al. Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet. 2009 Aug;2(4):389–395.
   PubMedGoogle Scholar
• Carrero JJ, Kyriazis J, Sonmez A, et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol. 2012 Feb;7(2):207–215.
   PubMed Web of Science ®Google Scholar
• Balbach L, Wallaschofski H, Völzke H, et al. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC Endocr Disord. 2013 Mar 21 13(1):12.
   PubMedGoogle Scholar
• Wang T, Lu J, Xu Y, et al. Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study. Diabetes Care. 2013 Jul;36(7):1974–1980.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Altinok M, Mumm H, et al. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome. Hum Reprod. 2014 Aug;29(8):1773–1779.
   PubMed Web of Science ®Google Scholar
• Wang T, Xu Y, Xu M, et al. Circulating prolactin and risk of type 2 diabetes: a prospective study. Am J Epidemiol. 2016 Aug 15 184(4):295–301.
   PubMed Web of Science ®Google Scholar
• Chahar C, Chahar K, Ankit BS, et al. Association of Serum prolactin level with impaired glucose regulation and diabetes. J Assoc Physicians India. 2017 Mar;65(3):34–39.
   PubMedGoogle Scholar
• Ruiz-Herrera X, de Los Ríos EA, Díaz JM, et al. Prolactin Promotes adipose tissue fitness and insulin sensitivity in obese males. Endocrinology. 2017 Jan 1 158(1):56–68.
   PubMed Web of Science ®Google Scholar
• Ponce AJ, Galván-Salas T, Lerma-Alvarado RM, et al. Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans. Endocrine. 2020 Feb;67(2):331–343.
   PubMed Web of Science ®Google Scholar
• Yang H, Lin J, Li H, et al. Prolactin is associated with insulin resistance and beta-cell dysfunction in infertile women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2021;12:571229.
   PubMed Web of Science ®Google Scholar
• Li J, Rice MS, Huang T, et al. Circulating prolactin concentrations and risk of type 2 diabetes in US women. Diabetologia. 2018 Dec;61(12):2549–2560.
   PubMed Web of Science ®Google Scholar
• Sorenson RL, Brelje TC. Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res. 1997 Jun;29(6):301–307.
   PubMed Web of Science ®Google Scholar
• Khant Aung Z, Kokay IC, Grattan DR, et al. Prolactin-induced adaptation in glucose homeostasis in mouse pregnancy is mediated by the pancreas and not in the forebrain. Front Endocrinol (Lausanne). 2021;12:765976.
   PubMed Web of Science ®Google Scholar
• Pepin ME, Bickerton HH, Bethea M, et al. Prolactin receptor signaling regulates a pregnancy-specific transcriptional program in mouse islets. Endocrinology. 2019 May 1 160(5):1150–1163.
   PubMed Web of Science ®Google Scholar
• Cao Y, Feng Z, He X, et al. Prolactin-regulated Pbk is involved in pregnancy-induced β-cell proliferation in mice. J Endocrinol. 2021 Dec 13 252(2):107–123.
   PubMed Web of Science ®Google Scholar
• Loke YK, Golder SP, Vandenbroucke JP. Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources. Ther Adv Drug Saf. 2011 Apr;2(2):59–68.
   PubMedGoogle Scholar
• Corona G, Giagulli VA, Maseroli E, et al. THERAPY OF ENDOCRINE DISEASE: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016 Mar;174(3):R99–116.
   PubMed Web of Science ®Google Scholar
• Al Dahmani KM, Almalki MH, Ekhzaimy A, et al. Proportion and predictors of hypogonadism recovery in men with macroprolactinomas treated with dopamine agonists. Pituitary. 2022 Jul 6 25(4):658–666.
   PubMed Web of Science ®Google Scholar
• Cozzi R, Ambrosio MR, Attanasio R, et al. Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors. Eur J Endocrinol. 2022 Feb 3;186(3):1–33.
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273–288.
   PubMed Web of Science ®Google Scholar
• Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest. 2016 Sep;39(9):967–981.
   PubMed Web of Science ®Google Scholar
• Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother. 2014 Sep;15(13):1903–1926.
   PubMed Web of Science ®Google Scholar
• Corona G, Mannucci E, Forti G, et al. Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes? Int J Androl. 2009 Oct;32(5):431–441.
   PubMedGoogle Scholar
• Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization. Eur J Endocrinol. 2020 Sep;8(5):970–987.
   Google Scholar
• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male. 2021 Dec;24(1):119–138.
   PubMed Web of Science ®Google Scholar
• Salonia A, Bettocchi C, Boeri L, et al. European Association of Urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol. 2021 Sep;80(3):333–357.
   PubMed Web of Science ®Google Scholar
• Retnakaran R, Ye C, Kramer CK, et al. Maternal serum prolactin and prediction of postpartum β-cell function and risk of prediabetes/diabetes. Diabetes Care. 2016 Jul;39(7):1250–1258.
   PubMed Web of Science ®Google Scholar
• Soto-Pedre E, Newey PJ, Bevan JS, et al. Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. Endocr Connect. 2017 Nov;6(8):580–588.
   PubMed Web of Science ®Google Scholar
• Toulis KA, Robbins T, Reddy N, et al. Males with prolactinoma are at increased risk of incident cardiovascular disease. Clin Endocrinol (Oxf). 2018 Jan;88(1):71–76.
   PubMed Web of Science ®Google Scholar
• Krogh J, Selmer C, Torp-Pedersen C, et al. Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality. Horm Metab Res. 2017 Jun;49(6):411–417.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Di Pasquale G, et al. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018 Sep;15(9):1260–1271.
   PubMed Web of Science ®Google Scholar
• Chaggar PS, Shaw SM, Williams SG. Effect of antipsychotic medications on glucose and lipid levels. J Clin Pharmacol. 2011 May;51(5):631–638.
   PubMed Web of Science ®Google Scholar
• Chan JKN, Chu RST, Hung C, et al. Mortality, revascularization, and cardioprotective pharmacotherapy after acute coronary syndrome in patients with severe mental illness: a systematic review and meta-analysis. Schizophr Bull. 2022 Jul 4 48(5):981–998.
   PubMed Web of Science ®Google Scholar
• Haring R, Völzke H, Vasan RS, et al. Sex-specific associations of serum prolactin concentrations with cardiac remodeling: longitudinal results from the Study of Health Pomerania (SHIP). Atherosclerosis. 2012 Apr;221(2):570–576.
   PubMed Web of Science ®Google Scholar